Novo Nordisk (NVO)

• Market cap: $298B
• 1 day: -0.27%
• 5 days: -3.65%
• 1 month: -12.96%
• 3 months: 6.62%
• 6 months: -19.30%
• Year to date: -23.40%
• 1 year: -52.41%
• 5 years: 104.20%
• 10 years: 128.26%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 77,406

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 617 | Existing positions reduced: 542

0.41% less ownership

Funds ownership: 9.94% [Q4 2024] → 9.53% (-0.41%) [Q1 2025]

9% less funds holding

Funds holding: 1,640 [Q4 2024] → 1,498 (-142) [Q1 2025]

23% less funds holding in top 10

Funds holding in top 10: 31 [Q4 2024] → 24 (-7) [Q1 2025]

24% less capital invested

Capital invested by funds: $30.1B [Q4 2024] → $22.9B (-$7.21B) [Q1 2025]

26% less call options, than puts

Call options by funds: $987M | Put options by funds: $1.34B

43% less first-time investments, than exits

New positions opened: 140 | Existing positions closed: 246

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $64 5% downside
• Avg. target: $64 5% downside
• High target: $64 5% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

BMO Capital Evan David Seigerman

5% downside $64

Market Perform Downgraded

17 Apr 2025